Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Inclusion Criteria:

• Aged from 18 to 90 years old;

• Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);

• Prostate cancer detected by PSA or imaging examination, or clinically suspectedrecurrence after standardized treatment;

• simultaneous [18F]AlF-PSMA-N5 and [18F]F-DCFPyL examinations within two weeks;

• Willing to undergo surgery or needle biopsy for pathological examination afterexamination, or confirmed as prostate cancer by histopathology before or aftertreatment;

• Sign informed consent.

Exclusion Criteria:

• Patients who cannot cooperate with the examination;

• Concurrent malignant tumors;

• Previous alcohol allergy;

• Patients with liver and kidney dysfunction;

• Other circumstances deemed by the investigator to be inappropriate for trialparticipation.